UPDATE 1-Abbott seeks to grow non-pharma side of business

* Still interested in non-pharma acquisitions

* Can sustain growth projections without acquisitions

* Not interested in "mega deal" or "merger of equals"

CHICAGO, June 10 (Reuters) - Abbott Laboratories (ABT.N) Chief Executive Miles White said he maintains a "bias" toward building the non-pharmaceutical side of the company's business and is still interested in non-pharma acquisitions.

However, he added that he is not interested in a "mega deal" or a "merger of equals."

"That's not happening," the CEO said in response to a question at a Goldman investment conference, which was webcast.

He noted that Abbott, the maker of rheumatoid arthritis drug Humira, heart stents, eye care products and nutritional supplements, has targeted small- to medium-size deals in the past.

White, who is also chairman of the board, said Abbott could meet its financial goals without doing an acquisition. "I'd look for things to add, but I don't need to," he said.

He said he's particularly interested in products that would sell well in emerging markets because of the long-term growth prospects.

Separately, White said he was not concerned about underlying growth of Humira, whose sales dipped in the first quarter. He said he agreed with Wall Street analysts that annual sales of the drug could peak at $8 billion to $10 billion.

Chicago-based Abbott generated sales of $29.5 billion in 2008. Drugs made up about 57 percent of that total.

Its shares were down 8 cents to $44.27 in noon trading on the New York Stock Exchange. (Reporting by Debra Sherman; Editing by Tim Dobbyn)